Top

Published in:

01-09-2014 | Research Article

Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in oral squamous cell carcinoma (OSCC) and promotes migration, invasion and epithelial–mesenchymal transition (EMT) in SCC15 cells

Authors: Enjiao Zhang, Shuang Liu, Zhongfei Xu, Shaohui Huang, Xuexin Tan, Changfu Sun, Li Lu

Published in: Tumor Biology | Issue 9/2014

Abstract

Pituitary tumor-transforming gene 1 (PTTG1) is an important oncogenic transcription factor implicated in various malignancies, including oral squamous cell carcinoma (OSCC), a common malignancy of head and neck. Although PTTG1 is reportedly overexpressed in OSCC tissues, its role in human OSCC remains elusive. Thus, this study was conducted to explore the correlation between PTTG1 expression and tumorigenesis of OSCC. We first examined PTTG1 mRNA and protein expression in 28 pairs of OSCC tissues and adjacent non-tumor tissues. PTTG1 protein levels in 98 OSCC specimens were also evaluated by using immunohistochemistry. Our data showed that both mRNA and protein expression levels of PTTG1 in OSCC tissue specimens were markedly higher than that in the corresponding non-tumor tissue samples. A high level of PTTG1 protein expression was found in 74 out of 98 cases (75.51 %) and it was correlated with lymph node metastasis (P = 0.002) and tumor–node–metastasis (TNM) stage (P = 0.007) of patients with OSCC. Moreover, forced overexpression of PTTG1 enhanced SCC15 cell migration and invasion, whereas knockdown of PTTG1 resulted in reverse phenomena. In addition, elevated PTTG1 also increased the activities and expressions of matrix metalloproteinase (MMP)-2, and enhanced epithelial–mesenchymal–transition (EMT) process in SCC15 cells. The EMT changes were accompanied by downregulation of epithelial cadherin (E-cadherin) protein expression and upregulation of snail and vimentin. In summary, our results illustrate that PTTG1 may contribute to the development and progression of human OSCC.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36. doi:10.3322/caac.20121.CrossRefPubMed

Han S, Chen Y, Ge X, Zhang M, Wang J, Zhao Q, et al. Epidemiology and cost analysis for patients with oral cancer in a university hospital in China. BMC Public Health. 2010;10:196. doi:10.1186/1471-2458-10-196.PubMedCentralCrossRefPubMed

Dantas DD, Ramos CC, Costa AL, Souza LB, Pinto LP. Clinical–pathological parameters in squamous cell carcinoma of the tongue. Braz Dent J. 2003;14(1):22–5.CrossRefPubMed

Bodner L, Manor E, Friger MD, van der Waal I. Oral squamous cell carcinoma in patients twenty years of age or younger — review and analysis of 186 reported cases. Oral Oncol. 2014;50(2):84–9. doi:10.1016/j.oraloncology.2013.11.001.CrossRefPubMed

Dionne KR, Warnakulasuriya S, Binti Zain R, Cheong SC. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory. Int J Cancer. 2014. doi:10.1002/ijc.28754.PubMed

Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997;11(4):433–41. doi:10.1210/mend.11.4.9911.CrossRefPubMed

Tong Y, Eigler T. Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol. 2009;43(5):179–85. doi:10.1677/JME-08-0176.CrossRefPubMed

Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrinol Relat Cancer. 2008;15(3):721–43. doi:10.1677/ERC-08-0012.CrossRef

Wang Z, Melmed S. Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter. Endocrinology. 2000;141(2):763–71. doi:10.1210/endo.141.2.7294.PubMed

10.

Chesnokova V, Melmed S. Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol. 2010;326(1–2):55–9. doi:10.1016/j.mce.2010.02.012.PubMedCentralCrossRefPubMed

11.

Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet. 2000;355(9205):716–9. doi:10.1016/S0140-6736(99)10238-1.CrossRefPubMed

12.

Panguluri SK, Yeakel C, Kakar SS. PTTG: an important target gene for ovarian cancer therapy. J Ovarian Res. 2008;1(1):6. doi:10.1186/1757-2215-1-6.PubMedCentralCrossRefPubMed

13.

Wondergem B, Zhang Z, Huang D, Ong CK, Koeman J, Hof DV, et al. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer Res. 2012;72(17):4361–71. doi:10.1158/0008-5472.CAN-11-2330.CrossRefPubMed

14.

Grizzi F, Di Biccari S, Fiamengo B, Stifter S, Colombo P. Pituitary tumor-transforming gene 1 is expressed in primary ductal breast carcinoma, lymph node infiltration, and distant metastases. Dis Markers. 2013;35(4):267–72.PubMedCentralCrossRefPubMed

15.

Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013;34(9):2145–55. doi:10.1093/carcin/bgt158.CrossRefPubMed

16.

Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2006;43(5):1042–52. doi:10.1002/hep.21137.CrossRefPubMed

17.

Liao LJ, Hsu YH, Yu CH, Chiang CP, Jhan JR, Chang LC, et al. Association of pituitary tumor transforming gene expression with early oral tumorigenesis and malignant progression of precancerous lesions. Head Neck. 2011;33(5):719–26. doi:10.1002/hed.21531.CrossRefPubMed

18.

Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005;55(4):242–58. quiz 61–62, 64.CrossRefPubMed

19.

Chen CJ, Hsu LS, Lin SH, Chen MK, Wang HK, Hsu JD, et al. Loss of nuclear expression of Kruppel-like factor 4 is associated with poor prognosis in patients with oral cancer. Hum Pathol. 2012;43(7):1119–25. doi:10.1016/j.humpath.2011.09.003.CrossRefPubMed

20.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.CrossRefPubMed

21.

Toth M, Sohail A, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol. 2012;878:121–35. doi:10.1007/978-1-61779-854-2_8.CrossRefPubMed

22.

Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10(6):415–33. doi:10.1006/scbi.2000.0379.CrossRefPubMed

23.

Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54. doi:10.1038/nrc822.CrossRefPubMed

24.

Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin–catenin cell–cell adhesion complex and human cancer. Br J Surg. 2000;87(8):992–1005. doi:10.1046/j.1365-2168.2000.01513.x.CrossRefPubMed

25.

Wu Y, Zhou BP. Snail: more than EMT. Cell Adhes Migr. 2010;4(2):199–203.CrossRef

26.

Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033–46. doi:10.1007/s00018-011-0735-1.PubMedCentralCrossRefPubMed

27.

Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res. 2003;9(2):551–4.PubMed

28.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74. doi:10.1038/nrc745.CrossRefPubMed

29.

Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16–27. doi:10.1111/j.1742-4658.2010.07919.x.CrossRefPubMed

30.

de Vicente JC, Fresno MF, Villalain L, Vega JA, Hernandez VG. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 2005;41(3):283–93. doi:10.1016/j.oraloncology.2004.08.013.CrossRefPubMed

31.

Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 2000;36(2):207–13.CrossRefPubMed

32.

Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR–MEK–ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol. 2012;40(5):1714–24. doi:10.3892/ijo.2011.1320.PubMed

33.

Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S, et al. Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-kappaB/MMP-2 signaling pathways. J Transl Med. 2013;11:132. doi:10.1186/1479-5876-11-132.PubMedCentralCrossRefPubMed

34.

Luo W, Liu Y, Zhang J, Luo X, Lin C, Guo J. Andrographolide inhibits the activation of NF-kappaB and MMP-9 activity in H3255 lung cancer cells. Exp Ther Med. 2013;6(3):743–6. doi:10.3892/etm.2013.1196.PubMedCentralPubMed

35.

Radisky DC. Epithelial–mesenchymal transition. J Cell Sci. 2005;118(Pt 19):4325–6. doi:10.1242/jcs.02552.CrossRefPubMed

36.

Chen C, Zimmermann M, Tinhofer I, Kaufmann AM, Albers AE. Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Lett. 2013;338(1):47–56. doi:10.1016/j.canlet.2012.06.013.CrossRefPubMed

37.

Shah PP, Kakar SS. Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin. Cancer Lett. 2011;311(1):66–76. doi:10.1016/j.canlet.2011.06.033.PubMedCentralCrossRefPubMed

38.

Yoon CH, Kim MJ, Lee H, Kim RK, Lim EJ, Yoo KC, et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem. 2012;287(23):19516–27. doi:10.1074/jbc.M111.337428.PubMedCentralCrossRefPubMed

39.

Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645–54. doi:10.1158/0008-5472.CAN-07-2938.CrossRefPubMed

40.

Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24(6):1838–51. doi:10.1096/fj.09-151639.PubMedCentralCrossRefPubMed

41.

Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13(3):332–7.CrossRefPubMed

42.

Hsu YH, Liao LJ, Yu CH, Chiang CP, Jhan JR, Chang LC, et al. Overexpression of the pituitary tumor transforming gene induces p53-dependent senescence through activating DNA damage response pathway in normal human fibroblasts. J Biol Chem. 2010;285(29):22630–8. doi:10.1074/jbc.M109.096255.PubMedCentralCrossRefPubMed

Title: Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in oral squamous cell carcinoma (OSCC) and promotes migration, invasion and epithelial–mesenchymal transition (EMT) in SCC15 cells
Authors: Enjiao Zhang
Shuang Liu
Zhongfei Xu
Shaohui Huang
Xuexin Tan
Changfu Sun
Li Lu
Publication date: 01-09-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2143-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma

Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7

RETRACTED ARTICLE: MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma

MTHFR gene polymorphism and risk of myeloid leukemia: a meta-analysis

The effect of TLX3 expression on the prognosis of pediatric T cell acute lymphocytic leukemia—a systematic review

Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer